Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic condition that causes progressive weakness and wasting of the muscles, particularly those in the face, shoulders, and upper arms.
ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy Type 1
We are studying a new treatment for adults with Facioscapulohumeral Muscular Dystrophy Type 1 to see how safe it is and how it works in the body. This trial will help us understand its effects with different doses.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 70 years old?
- Are you male or a nonpregnant, nonlactating female?
- Do you have a clinical severity score (CSS) between 3 and 8 (on a scale of 0 to 10)?
- Are you currently taking any medications that affect muscle function, like theophylline?
- Do you have any major heart problems, like heart failure or a history of heart attacks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Aro-Dux4
Ads-010
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
Department of Neurology
Klingenstein, Germany
Klinikum der Universitaet Muenchen AöR
Department of Neurology
Munich, Germany
Universitaet Muenster
Neurology
Münster, Germany
Sponsor: Arrowhead Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.